CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Crispant analysis in zebrafish serves as a powerful tool for the rapid functional screening of genes implicated in bone fragility disorders, like osteogenesis imperfecta and osteoporosis.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Recent TAU study demonstrates how a crucial but underexplored process of DNA transfer between bacteria affects its defense ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on RAPT Therapeutics (RAPT – Research Report), GE ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

Robert Machray, a veteran actor known for roles in Cheers as well as numerous other sitcoms and Broadway shows, died at his ...